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Background: Albumin binds low–molecular-weight mol-
ecules, including proteins and peptides, which then
acquire its longer half-life, thereby protecting the bound
species from kidney clearance. We developed an exper-
imental method to isolate albumin in its native state and
to then identify [mass spectrometry (MS) sequencing]
the corresponding bound low–molecular-weight mole-
cules. We used this method to analyze pooled sera from
a human disease study set (high-risk persons without
cancer, n 40; stage I ovarian cancer, n  30; stage III
ovarian cancer, n  40) to demonstrate the feasibility of
this approach as a discovery method.
Methods: Albumin was isolated by solid-phase affinity
capture under native binding and washing conditions.
Captured albumin-associated proteins and peptides
were separated by gel electrophoresis and subjected to
iterative MS sequencing by microcapillary reversed-
phase tandem MS. Selected albumin-bound protein
fragments were confirmed in human sera by Western
blotting and immunocompetition.
Results: In total, 1208 individual protein sequences
were predicted from all 3 pools. The predicted se-
quences were largely fragments derived from proteins
with diverse biological functions. More than one third
of these fragments were identified by multiple peptide
sequences, and more than one half of the identified
species were in vivo cleavage products of parent pro-
teins. An estimated 700 serum peptides or proteins were
predicted that had not been reported in previous serum
databases. Several proteolytic fragments of larger mol-
ecules that may be cancer-related were confirmed im-
munologically in blood byWestern blotting and peptide
immunocompetition. BRCA2, a 390-kDa low-abundance
nuclear protein linked to cancer susceptibility, was repre-
sented in sera as a series of specific fragments bound to
albumin.
Conclusion: Carrier-protein harvesting provides a rich
source of candidate peptides and proteins with potential
diverse tissue and cellular origins that may reflect
important disease-related information.
© 2005 American Association for Clinical Chemistry
The circulatory proteome holds great promise as a reser-
voir of information useful for disease detection and ther-
apeutic monitoring (1 ). Despite this potential, compre-
hensive characterization of the circulatory proteome is
difficult because of the wide dynamic range of protein
concentrations that exist between larger molecules such as
albumin (g/L) and the sought after biomarkers (below
ng/L) (2 ). Here we describe a method for amplifying the
yield of low-abundance, low–molecular-weight proteins
and peptide fragments in serum as a means of providing
a new window into the information content contained
within the circulation. This method takes advantage of the
tendency for low-abundance molecules to associate with
high-abundance proteins such as albumin and thereby
acquire the carrier’s longevity in the serum (3 ). This
report describes the application of this method to identify
candidate proteins and peptides in serum pools from
diseased and control ovarian cancer patients.
Current protocols for investigation of the serum pro-
teome often recommend prefractionation by native de-
pletion of high-abundance species (e.g., albumin, im-
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munoglobulins, lipoproteins) (4–8). This approach can
inadvertently remove a high percentage of candidate
low-abundance proteins and peptides because most low–
molecular-weight molecules in serum form complexes
with high-abundance proteins, which protect the bound
molecules from clearance and allow them to remain in
circulation. Albumin is the most abundant protein in
plasma and serum, present at 50 g/L, and has a half-life of
19 days in humans (9–11). Because the kidney generally
and efficiently filters out molecules 60 kDa, smaller
proteins and peptides will be protected from clearance by
association with albumin (9, 10). Plasma protein binding
can be an effective means of extending the pharmacoki-
netic properties of otherwise short-lived molecules (9, 11–
13). Dennis et al. (9 ) demonstrated that a 58-fold increase
in peptide longevity could be attained through albumin
binding and association. Albumin binding of biologically
important proteins and peptides is well documented. For
example, the amino-terminal peptide of HIV-1, gp41, and
the 14-kDa fragment of streptococcal protein G are known
to specifically bind with human serum albumin (14, 15).
Vitamin A transport and homeostasis is controlled by a
specific protein–protein interaction between the 21-kDa
retinol-binding protein and transthyretin, which was
shown to reduce glomerular filtration of the low–molec-
ular-mass retinol-binding protein (16 ).
It has recently been shown that most low–molecular-
weight molecules that have been visualized by mass
spectrometry (MS)6 profiling methods in the past exist
under native conditions in a complexed state with high–
molecular-weight proteins (17, 18). Direct analysis of the
low–molecular-weight portion of size-fractionated native
serum revealed few unbound molecular species. These
previous studies (3, 17, 18) demonstrated that most of the
low–molecular-weight species were found in the high–
molecular-weight fraction because they were all com-
plexed to other proteins. These same investigators went
on to denature the protein complexes and then sequenced
the size-fractionated low–molecular-weight repository.
The selectivity of binding of low–molecular-weight con-
stituents for different classes of carrier proteins was
explored further (17, 18), revealing that subsets of bound
low–molecular-weight peptides and sequenced protein
fragments associated with albumin were different from
those bound to immunoglobulin, apolipoprotein, and
transferrin (18 ). These previous studies established the
scientific rationale for the present investigation into the
carrier-protein–bound information archive. To evaluate
the possibility that this repository of bound molecules
contains potential disease-related information, we report
the results of an investigation comparing the albumin-
associated peptides in serum study sets derived from
patients with pathologically documented ovarian cancer
vs healthy but high-risk patients who had been disease-
free for 5 years after serum collection.
Two key properties of carrier proteins enable them to
function as efficient harvesters of lower-abundance puta-
tive biomarkers in the circulation: overwhelming relative
abundance and long half-lives compared with their cargo.
Considering the binding reaction between a biomarker (B)
and its carrier protein (C):
kf
B  C 3
4 BC
kr
it is reasonable to suppose that the reaction dynamics are
governed by mass action kinetics because a carrier protein
would not usually bind more than one molecule of the
biomarker of interest if the carrier existed in high relative
abundance.
Thus, the rate of formation of the biomarker–carrier-
protein complex (BC) is proportional to the product of the
biomarker concentration [B] and the carrier-protein con-
centration [C], with a constant of proportionality kf. The
dissociation of the biomarker–carrier-protein complex
into free biomarker and carrier protein, on the other hand,
is proportional to the concentration of the bound biomar-
ker [BC], with a constant of proportionality kr. The for-
ward and reverse reaction rates are given by:
Rf  kf [B][C]
and
Rr  kr [BC]
respectively. The vast excess of carrier protein means that
only a tiny proportion of its total concentration will be
consumed in the reaction with the biomarker, so that the
free carrier-protein concentration [C] may be considered a
constant. The free carrier-protein concentration may then
be absorbed into the forward rate constant to yield an
amplified effective forward rate constant, kf*, giving rise
to the forward reaction rate:
Rf kf
* [B]
where
kf
*  kf [C]
The reaction arrives at an equilibrium when Rf  Rr, or:
kf
* [B]  kr [BC]
Importantly, because the effective forward rate constant
kf* has been amplified by the (very large) carrier-protein
concentration, it is expected to be many orders of magni-
tude larger than the reverse rate constant kr, so that the
reaction between the biomarker and its carrier protein is
strongly biased in the forward direction. The equilibrium
6 Nonstandard abbreviations: MS, mass spectrometry; LC-MS/MS micro-
capillary reversed-phase tandem MS; and PVDF, polyvinylidene difluoride.
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ratio between the bound and free forms of the biomarker
is given by:
eq 
[BC]
[B]

kf
*
kr
Thus, the putative biomarker is likely to exist almost
entirely in complexed association with a carrier protein,
even when its innate binding affinity, characterized by the
“natural” forward rate constant, kf, is low (3 ). Indeed,
with an albumin concentration in the blood of 6  104
mol/L (19 ), molecules with low-affinity binding con-
stants, kf/kr, of 15  10
4 L/mol [reported for flavonoid
interaction with albumin (20 )] and 9.34  106 L/mol
[reported for interactions between protoporphyrins and
albumin (21 )] correspond to 98.9% and 99.98% probabil-
ity, respectively, that the molecule of interest will be
complexed with albumin.
Moreover, the relatively long half-life of the carrier
protein [19 days for albumin compared with a few
hours or less for an unbound molecule (9, 22–25)] facili-
tates the prolonged presence of smaller peptides and
proteins in the bloodstream. Mehta et al. (3 ) showed that
if a protein is secreted into the bloodstream at a constant
rate p, and is subsequently eliminated through the kid-
neys at a rate proportional to its concentration (with a
constant of proportionality of e), its steady-state concen-
tration in the circulation is given by the ratio p/e . In the
absence of carrier-protein binding, the steady-state con-
centration of biomarker in the circulation would be p
b
/e
b
,
where pb and eb are the production and elimination rates
of the biomarker, respectively. When bound to a carrier
protein, however, the biomarker acquires the carrier pro-
tein’s longer half-life, so that the steady-state concentra-
tion becomes p
b
/e
c
, where ec is the relatively small elim-
ination rate of the carrier protein. Because the elimination
rate of a protein is inversely proportional to its half-
life, amplification of the biomarker’s concentration in
the bloodstream as a result of carrier-protein binding
is e
b
/e
c
 t
1/ 2c
/t
1/ 2b
, where t(1/2)c and t(1/2)b are the
half-lives of the carrier protein and biomarker, respec-
tively. Thus, the longer the half-life of the carrier protein,
the greater is its ability to amplify the concentration of
bound species in the bloodstream. In this way, the relative
abundance of large carrier proteins and their longer
half-lives work together to increase the total concentration
of complexed molecules in the bloodstream. This report
describes the application of the carrier-protein sequestra-
tion principle to the isolation and mass spectrometric
identification of candidate low–molecular-weight pro-
teins and peptides that exist in the serum of ovarian
cancer patient disease study sets.
Materials and Methods
clinical serum samples
Serum samples were collected under full patient consent
and Institutional Review Board approval. Serum was
collected before physical evaluation, diagnosis, and treat-
ment and stored at 80 °C. The ovarian study set con-
sisted of 40 samples from unaffected, high-risk patient, 30
samples from patients with stage I ovarian cancer, and 40
samples from patients with stage III ovarian cancer. The
gynecologic oncology clinic where the samples from the
cases were collected is located in a building that is
separate but contiguously linked to the building in which
the National Ovarian Cancer Early Detection Program at
Northwestern University is located, where the high-risk
control samples were collected. A special attribute of this
sample set is that the same personnel were involved in the
blood collection, handling, and storage of all biospeci-
mens. In addition, all blood specimens were processed in
an identical manner under the same methodology.
Healthy control sera were collected from unaffected
women determined to be at increased risk for ovarian
cancer. These women were enrolled in the National
Ovarian Cancer Early Detection Program and had no
evidence of any cancer for 5 years as determined by twice
yearly 3-dimensional color Doppler ultrasound and ex-
tensive clinical evaluation by a board-certified gyneco-
logic oncologist.
Increased risk was determined by classic genetic ped-
igree analysis and by the presence or absence of factors
such as BRCA mutation status. The determination of
increased risk was based on commercially available com-
puter-generated risk algorithm programs such as BRCA
Pro. All patients in the high-risk clinic were seen by
board-certified genetic counselors and geneticists who
defined the risk. Similarly, the serum specimens from
women with ovarian cancer were procured in a gyneco-
logic oncology clinic from symptomatic women who were
later surgically staged and found to have epithelial ovar-
ian carcinoma. Each sample was accompanied by a veri-
fied pathology diagnosis. Briefly, specimens were col-
lected in red-top Vacutainer Tubes and allowed to clot for
1 h on ice, followed by centrifugation at 4 °C for 10 min at
1210g. The serum supernatant was divided in aliquots
and stored at80 °C until needed. Samples were selected
for our analysis by a random process categorized by the
pathology diagnosis as cancer or benign.
capture of native serum albumin and elution
of complexed protein species
A schematic representation of the basic experimental
technique is illustrated in Fig. 1. Native, diluted serum is
introduced into an affinity column so that the carrier
protein (albumin) is captured along with any bound
molecules. The bound subproteome consisting of the
carrier proteins and their peptide “cargo” is eluted, dis-
sociated, and separated by 1-dimensional gel electro-
phoresis. Each entire gel lane is cut out, finely subdivided
into molecular mass regions, subjected to in-gel trypsin
digestion, and prepared for electrospray mass spectro-
metric analysis.
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purification of albumin and bound peptide
Typically, 25 L of human stage-specific (pooled) cancer
serum (3.1 mg of protein) was diluted to 200 L with
Equilibration Buffer (Millipore) and run through a (Mon-
tage) albumin-specific affinity column twice. The bound
protein was washed thoroughly with two 200-L volumes
of proprietary wash buffer (provided by the manufac-
turer). These fractions were combined and labeled as a
“flow-through” fraction. The bound proteins were eluted
from the column by equilibrating with acetonitrile–H2O–
trifluoroacetic acid (70:30:0.2 by volume) for 30 min,
followed by a slow spin-through of the elution mixture,
repeated once. The eluate (retentate fraction) was lyoph-
ilized to 10 L in a HetoVac roto (CT 110) and recon-
stituted in an H2O–acetonitrile–formic acid (95:5:0.1 by
volume) buffer. Samples were desalted with a ZipTip
cleanup and reconstituted in a 1:1 mixture of water and
sodium dodecyl sulfate sample buffer (20 L total vol-
ume).
1-dimensional protein gel separation and
digestion
The flow-through and retentate fractions were kept on ice
in 20 L of sample buffer from 25 L of original serum,
and then were heated for 5 min at 95 °C and loaded on
1-dimensional precast gels to separate albumin from the
proteins/peptides/fragments of interest. The proteins
and fragments were visualized with a Gel Code Blue Stain
Reagent (Pierce) according to the manufacturer’s proto-
cols. The entire lane was excised from the gel and finely
sliced into very small molecular-weight regions (35
slices/lane). Gel bands were reduced, alkylated, and
digested with porcine modified trypsin according to a
Fig. 1. Schematic representation of the experimental technique.
Raw serum is introduced into a Millipore albumin depletion column. Albumin complexed with other proteins and peptides is retained. After gentle washing under native
conditions, the protein and peptide cargo are dissociated with organic solvent. Eluted proteins are fractionated by 1-dimensional (1D) gel electrophoresis followed by
in-gel trypsin digestion and subjected to LC-MS/MS analysis.
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standard protocol (26 ), and peptides were concentrated
and prepped for mass spectrometric analysis.
microcapillary reversed-phase tandem ms
Samples were lyophilized to near dryness and reconsti-
tuted in 6.3 L of Buffer A (H2O–acetonitrile–formic acid;
95:5:0.5 by volume) for MS analysis. Microcapillary re-
versed-phase tandem MS (LC-MS/MS) analysis was
performed with a Dionex LC Packings liquid chromatog-
raphy system coupled on-line to a ThermoFinnigan LCQ
Classic ion trap mass spectrometer with a modified nano-
spray source. Reversed-phase separations were per-
formed on an in-house, slurry-packed capillary column.
The C18 silica-bonded column was a 10-cm long (75-m
i.d.) fused-silica column packed with 5-m beads (pore
size, 300 Å; Vydac). A PepMap C18 cartridge (5-mm;
Dionex) acted as a desalting column. Sample was injected
in microliter pick-up mode and washed with Buffer A for
5 min before elution with a linear gradient with buffer B
(acetonitrile–H2O–formic acid; 95:5:0.1 by volume) up to
85% over 95 min at a flow rate of 200 nL/min. Full MS
scans were followed by 4 MS/MS scans of the most
abundant peptide ions (in a data-dependent mode), and
collision-induced dissociation was performed at a colli-
sion energy of 38% with the ion spray voltage set to
1.80 kV, capillary voltage set to 22.80 V and temperature
set to 180 °C.
data analysis and repetitive sequencing
Data analysis was performed by searching MS/MS spec-
tra against the European Bioinformatics Institute of the
nonredundant proteome set of Swiss-Prot, TrEMBL, and
Ensembl entries through the Sequest Bioworks Browser
(ThermoFinnigan), with a static modification of 57 Da
on cysteine residues and a dynamic modification for
oxidation of methionine of 15.9994 Da. Peptides were
considered legitimate hits after the correlation scores
(refer below) were filtered and the MS/MS data were
manually inspected. The criteria used to filter data in this
report are at least as stringent as most literature citations
(17, 18, 27–30):
Charge Xcorr 	Cn Rsp
1 
1.9 
0.1 1
2 
2.2 
0.1 1
3 
3.5 
0.1 1
Accepted peptide hits were required to have an Xcorr
ranking  1 relative to all other peptides in the database.
The albumin extraction, gel electrophoresis, protein diges-
tion/extraction, and LC-MS/MS analysis were repeated
in 5 subsequent trials, each time yielding diminishing
returns of new identifications for low-abundance peptide
hits. Repetitive sequencing of peptides in multiple trials
was an additional means to validate the reproducibility of
our experimental procedure, both within and between
cancer stages.
validation by serum western blotting
The primary antibody that recognized BRCA2 was syn-
thesized in house. Rabbits were immunized with a pep-
tide corresponding to an exact antigenic region of BRCA2,
and the resulting polyclonal anti-BRCA2 antibody was
affinity-purified (see below). The specificity of the anti-
body was verified against the full-length (390 kDa)
BRCA2 protein extracted from HeLa cell nuclear extract.
Subsequent preincubation of the primary antibody with
an immunizing synthetic peptide overlapping the anti-
genic region of interest successfully competed away the
representative band of native BRCA2 at 390 kDa. After
verification of the specificities of the antibody and com-
petition peptide, this experimental procedure was applied
to pooled ovarian cancer and control serum samples.
Prepared serum samples were heated for 5 min at 95 °C
in sample buffer containing 20 mL/L -mercaptoethanol,
followed by centrifugation at 10 000g for 1 min to remove
insoluble material. Samples were then subjected to 1-
dimensional electrophoresis and electroblotting at 30 V
for 2 h on ice. Membranes were incubated overnight at
4 °C in 50 g/L nonfat dry milk, 75 g/L glycine, and 1
mL/L Tween 20 in water to block unoccupied protein
binding sites.
The blocked membranes were rinsed twice with wash
buffer [10 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 1 g/L
bovine serum albumin, 1 mL/L Tween 20] and then
incubated with 1 mg/L primary antibody in wash buffer
containing 50 g/L nonfat dry milk, with rocking, for 2 h at
room temperature. For peptide blocking/competition as-
says, 10 g of primary antibody was incubated with 100
g of the corresponding immunization peptide in 400 L
of wash buffer for 1 h at room temperature with end-over-
end mixing. The peptide-treated antibody solution was
diluted to 10 mL (1 mg/L final antibody concentration) in
wash buffer containing 50 g/L nonfat dry milk before
incubation with polyvinylidene difluoride (PVDF) mem-
brane.
The membranes were washed 5 times (3 min each) in
50 mL of wash buffer and subsequently incubated in
10 mL of horseradish peroxidase–conjugated goat anti-
rabbit IgG (1:50 000 in wash buffer) for 1 h at room
temperature. After the PVDF membranes were washed
thoroughly, signals were developed by enhanced chemi-
luminescence.
peptide-specific antibodies
A peptide representing amino acid residues 980–993
(DKIPEKNNDYMNKW) of the BRCA2 sequence was
synthesized (Anaspec) and conjugated to keyhole limpet
hemocyanin for immunization as described previously
(31 ). The resulting antisera were affinity-purified over
columns of peptides conjugated to Affigel 15 (Bio-Rad)
and concentrated in stirred cells with YM-30 membranes
(Millipore). The concentrates were subjected to gel-filtra-
tion chromatography on 2.6  60 cm Superdex 200
columns (GE Healthcare) in phosphate-buffered saline,
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and the monomeric IgG fractions were pooled and con-
centrated. The protein concentrations were determined by
the Bradford assay (Bio-Rad).
Results
The ovarian cancer study set was divided according to
disease category; serum samples within each disease
category were pooled into sets. A total of 110 samples
were classified based on pathology into high-risk (n 40),
stage I (n  30), and stage III (n  40) ovarian cancer
pools, and 5 separate aliquots per disease stage were
iteratively sequenced by the experimental procedure in
Fig. 1. A total of 1208 unique proteins were predicted in
all 3 pools, 446 of these from multiple peptide sequences.
An iterative sequencing approach examines the repetitive
yield and variability between runs and between stage
classifications. The aggregate yield of low-abundance
protein identifications is expected to increase with re-
peated iterations of the experimental method. The corre-
lation between the number of sequencing iterations per-
formed and the total number of peptide sequences, and
corresponding protein identifications obtained are de-
scribed in Table 1. Overall, the number of unique proteins
identified by multiple peptide sequences increased at a
diminishing rate relative to the number of iterations
performed. The rates of single and multiple peptide hits
accumulated vs the number of experimental iterations are
shown in Fig. 2. The ability to identify new peptides with
multiple hits began to diminish by the third iteration
(Table 1 and Fig. 2); however, the total number of new
peptide identifications and single hit identifications con-
tinued to increase even after 5 iterations. Previous work
by Liu et al. (32 ) revealed that saturation of new peptide
identification occurs at around the 10th iteration. The
results presented here support the conclusion that greater
coverage of lower-abundance proteins can be achieved by
increasing the number of experiments performed on a
given sample.
Table 1. Representation of the total number of peptide hits and protein identifications acquired after subsequent iterations
of the experimental method for ovarian cancer stage-specific and normal sera.
Ovarian cancer
pool
No. of patient
samples in pool
No. of
iterations
No. of unique
protein IDsb
No. of peptides
sequenced
No. of
multipeptide
protein IDs
No. of
single peptide
protein IDs
High risk 40 5 359 935 147 212
4 334 908 144 190
3 282 838 140 142
2 235 720 133 102
1 164 565 106 58
Stage I 30 5 453 1027 149 304
4 425 998 148 277
3 386 921 142 244
2 298 732 132 166
1 168 594 111 57
Stage III-IV 40 5 396 896 150 246
4 358 848 148 210
3 301 761 144 157
2 253 694 140 113
1 185 560 123 62
a The number of patient samples pooled for each group is indicated. We performed 5 iterations for each category and report the total number of peptides sequenced
correlating to the total number of unique proteins identified. The protein identifications are classified as single or multiple peptide hits.
b ID, identification. Identified proteins are listed in the online Data Supplement.
Fig. 2. Number of protein identifications and peptide sequences found
relative to the number of iterations of the experimental procedure.
The recurring yield of peptide identifications (IDs) is plotted vs the number of
independent experimental sample iterations. Each successive iteration repre-
sents a separate, new aliquot of the serum pool. Multipeptide identifications
reached a plateau earlier in the iteration cycle. , total identifications; f,
multiple peptide identifications; Œ, single peptide identifications.
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We have identified 
700 different tryptic peptides
derived from proteins not previously reported to exist in
the blood in published databases from sera from women
with various stages of ovarian cancer; many of these
proteins are of low abundance (see Tables 1a–1c of the
Data Supplement that accompanies the online version of
this article at http://www.clinchem.org/content/vol51/
issue10/). More than 100 proteins falling into putative
functional categories (Fig. 3) previously known to be
related to cancer were identified by single or multiple
peptide hits. In this study, unique single peptide hits were
often discovered more than once from the same disease
category (Table 1b of the online Data Supplement). That
is, the same single peptide hit was generated more than
once from different aliquots of the same disease category.
Low-abundance proteins or peptides derived from
tissues entering the serum compartment can become
complexed with high abundance proteins (3, 9–17, 32). At
least one half of all the proteins identified, which were
bound to albumin and thus sequenced by the present
method, must exist as peptide fragments of whole pro-
teins. This is supported by two points of evidence: (a) the
peptides were sequenced from a molecular-weight region
of a gel that did not correspond to the predicted mass of
the intact protein; and (b) passive diffusion of protein
species through the vascular walls is hindered above
apparent molecular masses of 60 kDa (25 ). Thus, large
tissue proteins can be represented in the blood circulation
only if they are actively secreted or if they are in vivo
cleavage products of the parent protein. BRCA2, which
was sequenced by LC-MS/MS and represented by 4
distinct peptides (example BRCA2 spectra from 2 itera-
tively found peptides are presented in Fig. 4) and subse-
quently validated by competition Western blotting (Fig.
5C), is not predicted to be in the blood circulation as an
intact protein. In fact, the parent protein with a known
molecular mass of 390 kDa was not found by serum
Western blotting (Fig. 5D). Shown in Fig. 5C are immu-
nocompetition results for 2 cleavage products of BRCA2
(12 and 25 kDa) that were identified by Western blot
analysis of pooled ovarian cancer sera. A rabbit was
immunized with a synthetic peptide representing amino
acid residues 980–993 (DKIPEKNNDYMNKW) of the
BRCA2 protein to produce a polyclonal antibody that
ultimately detected the BRCA2 fragments in serum. Com-
petition with the cognate peptide completely extin-
guished the 12- and 25-kDa bands. The estimated masses
of the immuno-fragments (12 and 25 kDa) represent 9%
by mass of the total parent protein. Furthermore, 3 other
additional and distinct peptides were sequenced (residues
1942–1959, 2390–2401, and 2447–2459) in a separate re-
gion of the parent protein. The close proximity of the
peptides containing amino acids 2390–2401 and 2447–
2459 suggests that they likely originate from a single
serum fragment of BRCA2 (Fig. 5, A and B).
Candidate proteins bound to albumin (Table 1; see also
Fig. 3. Functional categories of the predicted albumin-associated proteins identified for each of the stage-specific ovarian cancer and high-risk
control serum pools.
Serum pools are designated as high risk, stage I (stage 1), and stage III-IV (stage 3). IDs, identifications.
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Fig. 4. Representative MS/MS spectra of BRCA2 peptides.
(A), result for the BRCA2 peptide identified as MTLGQDLKSDISLNIDK. (B), result for the BRCA2 peptide identified as VSKISPCDVSLETSDICK.
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Tables 1a–1c of the online Data Supplement) are appar-
ently diverse in origin and span a wide variety of pre-
dicted physiologic functions (Fig. 3). The breadth of
biological and functional classes ranges from defense and
immunity to transcription regulation, apoptosis, and cell
adhesion. More than one half of the predicted proteins
that have been sequenced have no known function re-
ported in the literature. The relative abundances of the
different functional classes of those proteins found in
ovarian cancer samples are shown in Fig. 3. The diversity
of categories represented is characteristic of a typical
serum proteome (23, 26). The ovarian cancer serum pro-
teins that have been identified are listed in Tables 1a–1c of
the online Data Supplement, and are shown classified as
either multiple-peptide or single-peptide identifications.
A sequence for CA125, a known ovarian cancer marker
(33, 34), was predicted to exist in the stage III ovarian
cancer pool, but it was not found in either the stage I or
the high-risk serum pools.
Discussion
The data presented here indicate that high-abundance
serum carrier proteins such as albumin may act to seques-
ter low–molecular-weight peptide fragments in the blood.
Such sequestered peptides may provide a potentially rich
source of candidate disease-associated biomarkers for
subsequent clinical validation and provide a new oppor-
tunity to expand the knowledge base for the molecular
composition of the circulation. Although the present work
emphasizes the use of albumin, nonalbumin carrier pro-
teins, such as IgG or fibronectin, are associated with a
distinct subproteome within human sera (23 ). The
Fig. 5. Confirmation of the presence of BRCA2 peptide in serum.
(A), locations of the 4 peptide sequences of BRCA2 found by MS and the serum pool population origins. (B), synthetic peptide corresponding to the amino acid sequence
overlapping with the sequence found by MS was used as a blocking agent in immunocompetition Western blotting. All sequenced peptides are shown in a spatial
orientation within native BRCA2. (C), peptide identification by MS was confirmed by competition Western blot analysis using the peptide shown in B. Western blots of
pooled ovarian cancer are displayed in a dilution curve. Top row, standard Western blot using a polyclonal anti-rabbit primary antibody synthesized in house
corresponding to the antigenic region of BRCA2 found by MS. Middle row, the primary antibody is first incubated with a competition peptide specific for the identical
amino acid region of BRCA2 before Western blotting. Bottom row, negative control/background of the goat anti-rabbit secondary. The BRCA2 peptides highlighted are
evident at 12 and 25 kDa. The indication of peptide fragments in Western blots of serum is expected because the molecular mass of the parent BRCA2 protein is
390 kDa, an apparent mass much larger than what is known to be able to passively enter the blood stream. (D), Western blot using polyclonal anti-BRCA 2 antibodies
showing 2 example ovarian cancer sera (OS1 and OS2) compared with total nuclear lysate of HeLa cells (HNL). Absence of the full-length BRCA2 protein in the sera
is shown.
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method of albumin capture, elution of bound peptide and
protein fragments, fractionation, digestion, and MS se-
quencing was repeated on 5 independent aliquots of each
disease category serum pool. Because shown in Table 1,
this iterative-sequencing approach provided a means to
assess sequence discovery reproducibility within the
same serum pool sample. Iterative sample sequencing
indicated that after 5 rounds of iterations, the yield of
novel multiple-peptide predictions not identified in pre-
vious iterations appeared to increase more slowly. This
would be expected if the peptide sequences are being
randomly resampled from the same large population of
limited original candidates.
In theory, a similar list of protein fragments could be
generated by denaturing and size-fractionating of sera
because albumin fractionation and isolation would occur
first. This is, in fact, exactly what previous investigators
did in their analyses (17, 18). However, because many
current biomarker efforts begin by depletion of native
albumin (as well as depletion of other high-abundance
proteins such as immunoglobulins), the findings of this
study begin to more fully describe the molecular informa-
tion that is being lost by this method of sample prepara-
tion. Moreover, direct analysis of the albumin-bound
material allows for clearer understanding of the nature
and existence of the carrier-protein–bound low–molecu-
lar-weight information archive while minimizing issues
of small amounts of free/unbound material contaminat-
ing the analysis.
The total list of identified albumin-bound entities are
shown in Tables 1a–1c of the online Data Supplement
(http://www.clinchem.org/content/vol51/issue10/). This
list reveals a rich and previously undescribed information
archive of putative analytes, many of which had not been
described as being represented in the circulation. These
molecules aremostly fragments of larger proteins; thus, their
validation will necessitate the development of new immu-
nodetection reagents such as anti-peptide antibodies.
It is well known that highly abundant proteins are
identified by a larger number of peptides than are lower-
abundance proteins. The probability of selecting and
identifying a peptide from a low-abundance, and poten-
tially more interesting, protein is therefore much less. The
inherent complexity and large dynamic range of protein
concentrations of global proteome samples represents a
considerable barrier to obtaining multiple peptide identi-
fications for each protein. The large number of peptides
present in such mixtures greatly exceeds the capacity of
current data-dependent tandemmass spectrometers, even
when multidimensional fractionation is used (4, 35, 36).
In the present method we have endeavored to reduce this
barrier by isolating the major high-abundance protein
albumin and then examining the identity of its bound
species.
Predicted sequences according to the criteria outlined
in the Materials and Methods section fell into 2 categories:
(a) multiple peptide hits, and (b) single peptide hits.
Multiple peptide hits according to disease pool category
are presented in Table 1a of the online Data Supplement
by protein identity. Single peptide hits are listed in Table
1b and 1c of the online Data Supplement, along with the
corresponding specific predicted sequences. Low-abun-
dance proteins in blood are statistically likely to be
discovered by only a single peptide sequence as a func-
tion of the dynamic range of proteins in serum; conse-
quently, their probability of detection is low. Further-
more, many of the predicted serum species are peptide
fragments of larger parent proteins. This can be concluded
because a high percentage of the predicted proteins in
Tables 1a–1c of the online Data Supplement have a
full-length mass larger than albumin. Peptide fragments
have reduced numbers of trypsin domains compared
with the intact parent protein. Thus, a single peptide
prediction, if correct, can correspond to a low-abundance
peptide or a protein fragment with a reduced number of
trypsin domains compared with the parent molecule.
Because we conducted 5 independent isolation and se-
quence determinations for each disease category, single
hits that were discovered more than once could be tabu-
lated (Table 1b of the online Data Supplement). Single
peptide hits discovered more than once may have a
higher probability of being valid serum biomarkers than
do single-instance single peptide hits.
The relevance of single peptide hits has been addressed
recently (37 ). These investigators pointed out that the
elimination of single peptide hits from experimental re-
sults is scientifically unwarranted and detrimental to the
field in general (37 ). In fact, when so-called “one-hit
wonders” identified by isotope-coded affinity tag pro-
teomics were later assessed for validation by immunoas-
say detection, 
90% were found to retain the differential
expression state determined by the initial MS-based assay.
Moreover, in the present study, many of the same single-
hit tryptic fragments were iteratively and reproducibly
found in the same disease category. Finally, for small,
low-abundance fragments (with a low number of trypsin
cleavage sites), it is statistically likely that only a single hit
would be obtained in any given experimental cycle.
Although we identified 4 separate fragments for
BRCA2, which increased our confidence in the finding,
the fact that a majority of our protein identifications were
based on one-hit MS analysis does not diminish their
potential for potential validation. It is well known that
highly abundant proteins are identified by a larger num-
ber of peptides than are lower-abundance proteins. The
probability of selecting and identifying a peptide from a
low abundance, and potentially more interesting, protein
is therefore much less. The inherent complexity and large
dynamic range of protein concentrations of global pro-
teome samples represents a considerable barrier to obtain-
ing multiple-peptide identifications for each protein. The
large number of peptides present in such mixtures greatly
exceeds the capacity of current data-dependent tandem
mass spectrometers, even when multidimensional frac-
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tionation is used. Moreover, global proteomic studies
have consistently shown a low false-positive rate (i.e.,
5%) for peptide identification; therefore; for every incor-
rect one-hit wonder that is thrown out, 19 correct
identifications are also excluded. Excluding one-hit won-
ders from possible validation would decimate quantita-
tive proteomics studies that use isotope-coded affinity tag
reagents and phosphoproteomic experiments, which typ-
ically produce only single phosphopeptide identifications.
Many investigations have performed orthogonal valida-
tion experiments (e.g., Western analysis) that have con-
firmed that these qualitative and quantitative proteomic
results forthcoming from one-hit wonders are indeed
valid identifications (27, 38–42).
Ultimately all predicted peptide sequences, whether
single or multiple, must remain designated as “candi-
date” components of the human serum until they are
confirmed immunologically. Many of the predicted se-
quences were derived from molecular-weight fractions
smaller than the predicted size of the protein. We there-
fore concluded that the sequenced species existed as a
fragment of a larger parent molecule. Thus, the gel
migration location of the band could not be used to
identify the protein. Western blotting with peptide com-
petition was performed on the selected fragments identi-
fied by MS as belonging to BRCA2 to verify the identity of
selected mass spectrometric identifications (Fig. 5C).
BRCA2 is a well-studied tumor suppressor protein
related to the p53 pathway that is directly implicated in
familial breast cancer and ovarian cancer (43–46). Al-
though the role of BRCA2 in breast and ovarian cancer
predisposition is poorly understood, it is known that
mutations of the BRCA2 gene are responsible for one third
of hereditary breast cancer cases (45 ). The data in Fig. 5
suggest that at least 2 fragments of the BRCA2 parent
protein exist in blood. A single predicted trypsin-cleaved
peptide at amino acids 965–981 was identified in both
stage I and stage III ovarian cancer serum pools (Fig. 4A
and Fig. 5A). This peptide is represented in competition
Western blots by 2 distinct molecular-weight bands (Fig.
5C). It is likely that a fragment containing the peptide at
amino acids 965–981 would be cleaved at various residues
in vivo and could therefore be represented at multiple
molecular weights. This peptide was not predicted in
pooled high-risk ovarian cancer serum by MS analysis.
On the basis of evidence from the Western blots using a
BRCA2 polyclonal antibody and the fact that BRCA2 is
too large (390 kDa) to enter the blood circulation in its
native form, we conclude that BRCA2 can be represented
in the serum as one or more fragments and that at least 2
amino-terminal peptide fragments of BRCA2 25 kDa
can be validated by peptide competition for antibodies
that recognize an amino acid sequence adjacent to, and
overlapping with, the predicted peptide sequence. Addi-
tionally, 2 separate BRCA2 fragments encompassing no
less than the amino acid region from 2390–2459 and
1942–1959 (Fig. 4B) are predicted to exist in the serum
from mass spectral evidence of multiple peptide se-
quences identified in this region of BRCA2.
The current methodology applies carrier-protein se-
questering to a disease category pool of combined sera.
The methodology described here appears to be a success-
ful means to identify candidate proteins and peptides in
the sera of patients with known disease states. On the
basis of the predicted physiologic functions of the paren-
tal protein containing the peptide sequence, these proteins
and peptides can potentially be derived from tumor cells,
from the host microenvironment, or from interactions
between these two tissue compartments. Each pool con-
tained multiple serum specimens procured before pathol-
ogy-based diagnosis. The rationale for using a pool of
multiple serum samples is based on the conservative
assumption that even within the same histopathologic
diagnosis, cancer is a heterogeneous disease. Thus, a
biologically relevant molecule may be expressed only
within a subfraction of the cancer population. Pooling
samples is statistically the best means to identify a list of
candidate peptides and proteins that exist within subsets
of the pooled population.
The first disadvantage of using a pool of sera to
discover markers is that molecules present in a subset of
the combined samples are diluted within the pool. Al-
though an individual sample may have a high concentra-
tion of the putative protein or peptide, this sample is
diluted within the entire pool. Consequently, this averag-
ing effect will lower the concentration of any individual
molecule in the pool before sequence analysis. Lastly, a
candidate protein that is identified in one disease pool
(e.g., high risk) but not found in a second disease category
(e.g., stage I cancer) may still exist in the second category
at a concentration below a threshold for statistical sam-
pling probability. Currently we are performing competi-
tion Western blots on a large set of serum samples from
individual patients diagnosed as either high risk or with
stage I, III, or IV ovarian cancer to determine the extent by
which pooling samples limits the effectiveness of MS
sequencing detection. Despite these drawbacks, as shown
in Table 1 and in Tables 1a–1c of the online Data Supple-
ment, carrier-protein sequestration appears to yield a list
of predicted sequences derived from proteins predicted in
the literature to have diverse physiologic functions.
The predicted sequences presented in Tables 1a–1c of
the online Data Supplement demonstrate a rich diversity
of peptides and protein fragments in the sera. Although
the application of this method yielded different sets of
predicted sequences within the control and diseased
category pools, these proteins and peptides cannot be
considered as candidate diagnostic markers. Once high-
throughput means are developed to quantitatively mea-
sure each protein and peptide and accurately distinguish
specific biomarker fragments from their parent molecules,
proper clinical trial studies can examine the diagnostic
sensitivity and specificity of a selected panel of molecules.
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In conclusion, proteins and peptides associated with
serum carrier proteins such as albumin may constitute a
rich source of new additions to the human serum pro-
teome. The sequences identified by this means are pre-
dicted to be derived from proteins that have been shown
in the literature to serve a wide variety of physiologic
functions. We can hypothesize that these complexed pro-
teins and peptides may have originated from a range of
different tissues and cellular compartments. A large pro-
portion of the predicted sequences represent fragments of
larger molecules. A subset of these candidates may even-
tually be found suitable for full clinical diagnostic testing
in adequately powered objective study sets.
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